Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1624
This examiner grants 83% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18475520 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING LIGHT-EMITTING DEVICE | Non-Final OA | Samsung Display Co., Ltd. |
| 18532671 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18277522 | COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES | Non-Final OA | The Regents of the University of California |
| 19225710 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | Non-Final OA | Bayer Aktiengesellschaft |
| 18799303 | PTPN11 INHIBITORS | Non-Final OA | Board of Regents, The University of Texas System |
| 18797142 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Non-Final OA | Novartis AG |
| 18559805 | COMPOSITION COMPRISING AHAS AND/OR BHAS WHICH IS STABILIZED BY A COMBINATION OF MONOALKYL OR DIALKYL ISOSORBIDE, POLYETHYLENE GLYCOL-POLYPROPYLENE GLYCOL ETHER AND TWO HYDROGENATED OR NON-HYDROGENATED POLYOXYETHYLENATED PLANT OILS | Non-Final OA | L'OREAL |
| 18553870 | INSANITARY INSECT PEST CONTROL METHOD USING CONDENSED HETEROCYCLIC COMPOUND | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18708827 | ANTI-SARS-COV-2 DRUG | Non-Final OA | TOKYO UNIVERSITY OF SCIENCE FOUNDATION |
| 18960485 | SALTS OF TAM INHIBITORS | Non-Final OA | Incyte Corporation |
| 18825882 | PHARMACEUTICAL COMPOSITION INCLUDING RETINOIC ACID AND CARBOHYDRATE AND USE THEREOF | Non-Final OA | Mastery Biotech CO., LTD. |
| 18842728 | PCNA INHIBITORS AND USES THEREOF | Non-Final OA | CITY OF HOPE |
| 18169326 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | Non-Final OA | Promega Corporation |
| 18763757 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | Non-Final OA | CELGENE CORPORATION |
| 18833008 | METAP2 INHIBITORS AND USES THEREOF | Non-Final OA | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy